Aglaia Therapeutics becomes Ribonexus, signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology
Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome…